论文部分内容阅读
目的探讨δ-catenin在卵巢癌组织中的表达及临床意义。方法选取2005年1月至2008年8月在中国医科大学附属盛京医院手术切除的卵巢癌组织143例,并收集其临床病理特征。采用鼠抗人δ-catenin单克隆抗体以SP免疫组化法进行研究,并分析δ-catenin表达与临床病理因素的相关性。结果δ-catenin在11例正常卵巢组织中的表达为阴性或低表达,69.93%的卵巢癌(100/143)出现δ-catenin阳性表达,并且都是胞浆表达。δ-catenin表达阳性率在卵巢浆液性腺癌,子宫内膜样癌,黏液性腺癌和透明细胞癌中的阳性表达率分别为73.81%(62/84),67.57%(25/37),57.89%(11/19)和66.67%(2/3)。且δ-catenin在浆液性腺癌与其他类型卵巢癌中表达差异无统计学意义(阳性率分别为73.81%和64.40%,P=0.1957)。δ-catenin的表达在Ⅲ～Ⅳ期卵巢癌(Ⅲ期83.33%,Ⅳ期77.78%)中显著高于Ⅰ～Ⅱ期卵巢癌(Ⅰ期55.81%,Ⅱ期64.53%,P=0.0308)。结论δ-catenin在卵巢癌中过表达并且与FIGO分期正相关,δ-catenin可能成为卵巢癌诊断和治疗中的一个新靶点。
Objective To investigate the expression of δ-catenin in ovarian cancer and its clinical significance. Methods 143 patients with ovarian cancer surgically excised from Shengjing Hospital affiliated to China Medical University from January 2005 to August 2008 were selected and their clinical and pathological features were collected. The rat anti-human δ-catenin monoclonal antibody was used to study the expression of δ-catenin and clinicopathological factors. Results The expression of δ-catenin was negative or low in 11 cases of normal ovarian tissue, while the expression of δ-catenin was positive in 69.93% of ovarian carcinomas (100/143). The positive rates of δ-catenin expression in ovarian serous adenocarcinoma, endometrioid carcinoma, mucinous adenocarcinoma and clear cell carcinoma were 73.81% (62/84), 67.57% (25/37), 57.89% (11/19) and 66.67% (2/3) respectively. There was no significant difference in the expression of δ-catenin between serous adenocarcinoma and other types of ovarian cancer (positive rates were 73.81% and 64.40% respectively, P = 0.1957). The expression of δ-catenin was significantly higher in stage Ⅲ-Ⅳ ovarian cancer (83.33% in stage Ⅲ, 77.78% in stage Ⅳ) than in stage Ⅰ-Ⅱ ovarian cancer (55.81% in stage Ⅰ, 64.53% in stage Ⅱ, P = 0.0308). Conclusions δ-catenin is overexpressed in ovarian cancer and positively correlated with FIGO staging. Δ-catenin may be a new target in the diagnosis and treatment of ovarian cancer.